Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 3, 2027

Study Completion Date

January 30, 2029

Conditions
Biliary Tract Cancer
Interventions
DRUG

Ivonescimab

20 mg/kg IV infusion every 3 weeks

DRUG

FOLFOX regimen

oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks

Trial Locations (4)

Unknown

Cliniques universitaires Saint-Luc, Brussels

Institute Mutualiste Montsouris, Paris

Centre Eugène Marquis, Rennes

University College London, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cancer Research UK & UCL Cancer Trials Centre

OTHER

collaborator

Belgian Group of Digestive Oncology

OTHER

collaborator

Summit Therapeutics

INDUSTRY

lead

UNICANCER

OTHER